Ratings CLASSYS Inc.

Equities

A214150

KR7214150005

End-of-day quote Korea S.E. Other stock markets 06:00:00 2024-05-06 pm EDT			5-day change	1st Jan Change
37,700 ^KRW	-1.69%		-0.40%	-0.13%

2023	Tranche Update on CLASSYS Inc.'s Equity Buyback Plan announced on September 15, 2022.	CI
2023	Tranche Update on CLASSYS Inc.'s Equity Buyback Plan announced on September 15, 2022.	CI

Summary

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.

Strengths

Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
Thanks to a sound financial situation, the firm has significant leeway for investment.
Over the past year, analysts have regularly revised upwards their sales forecast for the company.
Analysts covering this company mostly recommend stock overweighting or purchase.
Analyst opinion has improved significantly over the past four months.
The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.

Weaknesses

The company benefits from high valuations in earnings multiples.
The company's "enterprise value to sales" ratio is among the highest in the world.
In relation to the value of its tangible assets, the company's valuation appears relatively high.
The company is highly valued given the cash flows generated by its activity.
The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
Over the past twelve months, analysts' consensus has been significantly revised downwards.

Ratings chart - Surperformance

Sector: Advanced Medical Equipment & Technology

	1st Jan change	Capi.	ESG Refinitiv
CLASSYS INC.	-0.13%	1.79B	-
THERMO FISHER SCIENTIFIC	+8.25%	219B	B
DANAHER CORPORATION	+7.46%	183B	B-
INTUITIVE SURGICAL, INC.	+15.21%	136B	B-
BOSTON SCIENTIFIC CORPORATION	+26.79%	107B	A-
SIEMENS HEALTHINEERS AG	-1.14%	63.07B	A-
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	+7.23%	52.55B	B+
EDWARDS LIFESCIENCES CORPORATION	+12.30%	51.28B	B+
AGILENT TECHNOLOGIES, INC.	+1.86%	41.21B	A
GE HEALTHCARE TECHNOLOGIES INC.	+5.25%	36.43B	-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes